(Q40284509)

English

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

scientific article published on 6 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (English)

1 reference

Europe PubMed Central

19 September 2017

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

N Karachaliou

1

1 reference

Europe PubMed Central

19 September 2017

N Ziras

2

1 reference

Europe PubMed Central

19 September 2017

K Syrigos

3

1 reference

Europe PubMed Central

19 September 2017

K Tryfonidis

4

1 reference

Europe PubMed Central

19 September 2017

E Papadimitraki

5

1 reference

Europe PubMed Central

19 September 2017

E Kontopodis

6

1 reference

Europe PubMed Central

19 September 2017

V Bozionelou

7

1 reference

Europe PubMed Central

19 September 2017

A Kalykaki

8

1 reference

Europe PubMed Central

19 September 2017

V Georgoulias

9

1 reference

Europe PubMed Central

19 September 2017

D Mavroudis

10

1 reference

Europe PubMed Central

19 September 2017

publication date

6 June 2012

1 reference

Europe PubMed Central

19 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

19 September 2017

70

1 reference

Europe PubMed Central

19 September 2017

1

1 reference

Europe PubMed Central

19 September 2017

169-176

1 reference

Europe PubMed Central

19 September 2017

https://scigraph.springernature.com/pub.10.1007/s00280-012-1901-3

0 references

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Taxanes and capecitabine in combination: rationale and clinical results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Capecitabine-docetaxel combination treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Clinical studies with epothilones for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1901-3

21 January 2018

Identifiers

10.1007/S00280-012-1901-3

1 reference

Europe PubMed Central

19 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40284509&oldid=1893439834"